Did you know?

Nearly 10% of new cancer cases diagnosed each year in the U.S. are hematologic malignancies, including leukemia, lymphoma and myeloma.

#AML remains a serious blood cancer with significant unmet need, underscoring the importance of continued innovation.

$SNTI

At Senti, our mission is to create a new generation of smarter medicines designed to outsmart complex diseases.

Through innovative Gene Circuit technology, we are advancing novel approaches with the potential to transform patient care.

$SNTI #AML #Leukemia #Oncology

#DidYouSee - BioTuesdays featured our CEO, Timothy Lu!

He discusses how the Company's Gene Circuit platform is advancing next-generation cell and gene therapies.

Read More: bit.ly/4f7zCjo

$SNTI #CellandGeneTherapy #Cancer

#StayInTheLoop

Get the latest updates from Senti Bio delivered straight to your inbox.

Sign up today: bit.ly/3ZVnb39

$SNTI #AML #Leukemia #Oncology

At Senti Bio, we are advancing intelligent Gene Circuits designed for next-generation cell and gene therapies with a focus on oncology.

Guided by our values: Be Bold, Better Together, Build to Last. We are working to tackle hard-to-treat diseases.

$SNTI #Leukemia #AML #Oncology

AML is the most common type of acute leukemia in adults, accounting for 80% to 85% of cases, with a 5-year survival rate of 31.7% in the United States at diagnosis.

$SNTI #AML #Leukemia #Oncology

Don’t miss the latest from Senti Biosciences!

Subscribe to email alerts for updates on our pipeline, research, and company news: bit.ly/3ZVnb39

$SNTI #Oncology #Leukemia

Our CEO, Tim Lu, highlighted a transformational milestone as positive FDA RMAT feedback advances SENTI-202 toward a potential registrational study in relapsed/refractory AML.

Read more here: bit.ly/4wv4mCD
$SNTI #AML #Oncology #CellTherapy

Our Chief Medical Officer, Kanya Rajangam, highlighted strong momentum for SENTI-202, supported by encouraging clinical activity, a favorable safety profile, and advancements in donor selection.

Learn more: bit.ly/4wv4mCD
$SNTI

Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program

bit.ly/4wv4mCD
$SNTI

Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase

bit.ly/4dpqGFi
$SNTI #CellTherapy #Oncology #AML

Senti Bio was founded to build a new generation of smarter medicines designed to address complex diseases using novel and unprecedented approaches.

$SNTI #AML #Oncology

This #WorldDNADay, we recognize the power of genetic science in advancing new approaches to cancer treatment.

At Senti Bio, we’re leveraging gene circuits to drive innovation in cell and gene therapy.

$SNTI #Oncology #AML

On #AMLWorldAwarenessDay, we recognize the urgency to advance research and bring forward new therapies. Because behind every diagnosis is a life, a family, and a future.

We acknowledge the importance of continuing to push science forward to create new possibilities for patients.

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

bit.ly/3QgGnqb
$SNTI #CellTherapy #Oncology #AML

Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies

bit.ly/4cgkRue
$SNTI #CellTherapy #Oncology #AML

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

bit.ly/3PBFecv
$SNTI #CellTherapy #Oncology #AML

Founded to develop a new generation of smarter medicines, Senti Biosciences is advancing innovative approaches to outsmart complex diseases and redefine what’s possible in medicine.

$SNTI #Oncology #AML

Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference

bit.ly/4t6OzHS
$SNTI #CellTherapy #Oncology #AML

Want to hear about our latest progress?
Stay in the loop by signing up for our email alerts.
bit.ly/3ZVnb39

$SNTI #Oncology #AML